Korean J Med.  2003 Jul;65(1):59-65.

Effects of preoperative cisplatin and adriamycin chemotherapy for non-metastatic osteosarcoma

• Oh HA
• Lee G
• Kang HJ
• Lee JL
• Lee KH
• Hyun MS
• Sin DS
• Bae SH
• Ryoo HM

Abstract

BACKGROUND: Adjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. We studied the effectiveness of preoperative cisplatin and adriamycin combination chemotherapy in non-metastatic osteosarcoma.
METHODS
Twenty four cases of patient with osteosarcoma were divided into two groups except four patients treated only conservatively. Group A (14 patients) received chemotherapy before operation and Group B (6 patients) received chemotherapy after operation. The chemotherapy regimen consisted of cisplatin (120 mg/m2 on day 1) and adriamycin (adriamycin 25 mg/m2 on days 2 to 4).
RESULTS
The average age of the 20 patients was 27.5 years and the median follow-up duration was 39.3 months. 12 patients of group A were treated with limb-salvage operation and 2 patients with amputation because of tumor growing. According to Kaplan-Meier's plot, one year, three year overall survival rate were 100%, 85% in Group A and 100%, 75% in Group B. Histologic responses were assessed in patients received preoperative chemotherapy. Tumor necrosis over 90% is noted in 9 patients, under 90% necrosis is noted 5 patients. Their mean survival was 82 months and 25 months, respectively (p>0.05). CONCLSUION: Adjuvant chemotherapy with cisplatin and adriamycin was feasible in non-metastatic osteosarcoma and clinically significant adverse effect was neutropenia.

Keyword

Osteosarcoma; Chemotherapy; adjuvant; Limb Salvage

MeSH Terms

Amputation
Chemotherapy, Adjuvant
Cisplatin*
Doxorubicin*
Drug Therapy*
Drug Therapy, Combination
Follow-Up Studies
Humans
Limb Salvage
Necrosis
Neutropenia
Osteosarcoma*
Survival Rate
Cisplatin
Doxorubicin